BioTuesdays

Category - Developments

Kitov Pharma

Kitov Pharma prices U.S. IPO

Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be...

Can-Fite

Can-Fite expands development of CF102 into NASH

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...

Viking Therapeutics Logo

Viking, Kennedy Krieger to collaborate in X-ALD

Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...

Viking Therapeutics Logo

Viking submits IND for Phase 2 trial of VK2809

Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...

Dipexium Pharmaceuticals

Dipexium Phase 3 Locilex trials 62% enrolled

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled...

Avivagen

Avivagen, COFCO to conduct OxC-beta trial on pigs

Avivagen (TSX-V:VIV) and COFCO Nutrition and Health Research Institute (NHRI), an affiliate of the Chinese government’s COFCO Group, have agreed to conduct a trial of OxC-beta Livestock as a feed additive for swine. The...

Avivagen

Avivagen in credit facility with Bloom Burton

Avivagen (TSX-V:VIV) has signed an agreement with the Bloom Burton Healthcare Lending Trust for a secured drawdown credit facility of up to $1.8-million. The facility will advance Avivagen’s plans for commercializing...

Transition Therapeutics

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.